ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/skin
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Melanoma and skin / Skin
22
trial(s) found.
NCT06926075
Advanced
Phase 1
Not yet recruiting
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NCT06305962
Advanced
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06288191
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II to IV (M0) Resectable Cutaneous Squamous Cell Carcinoma (
MIA2023-490
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06151236
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell Carcinoma (
MIA2023-489
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Merkel cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05025813
Curative
Phase 2
Recruiting
A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab -
DESQUAMATE
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04830124
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma -
ARTISTRY-6
IL-2 fusion protein
anti-PD-1 monoclonal antibody
Cutaneous melanoma
Mucosal melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT03787602
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve (
KRT-232-103
)
MDM2 inhibitor
anti-PD-L1 monoclonal antibody
Merkel cell carcinoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03534947
Curative
Phase 2
Recruiting
A Pilot Study to Evaluate Short Term Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinomas in Cosmetically Challenging Locations (
SONIB
)
SMO inhibitor,first generation
topical immune response modifier
Carcinoma
Cutaneous basal cell carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
ACTRN12625000197437
Advanced
Phase 2
Not yet recruiting
A single arm, phase II trial of Cemiplimab in Head and Neck Cutaneous Squamous Cell Carcinoma with Large Nerve Perineural Spread (
NIL-Known
)
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Skin cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12618001573246
Advanced
Phase 2
Not yet recruiting
A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (
CRIO
) in locally and/or regionally advanced cutaneous squamous cell carcinoma
Carboplatin
Durvalumab
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
Skin cancer
Squamous cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12618001351202
Curative
Not Applicable
Not yet recruiting
A prospective case series evaluating neo-adjuvant use of Vismodegib in patients with periocular basal cell carcinoma to evaluate reduction in clinical and surgical tumour margins
SMO inhibitor,first generation
Cancer
Cutaneous basal cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12615001088538
Advanced
Phase 2
Recruiting
The effect of topical imiquimod or diphenylcyclopropenone on complete clinical response in patients with cutaneous in-transit melanoma metastases - A Phase II Single Centre Prospective Randomised Pilot Study. (
TIDAL-Melanoma
)
topical immune response modifier
Cutaneous in-transit melanoma metastasis
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06295809
Curative
Phase 2 / Phase 3
Active not recruiting
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007). (
V940-007
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06036836
Advanced
Phase 2
Active not recruiting
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010) (
4280A-010
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Endometrial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05888844
Advanced
Phase 2
Active not recruiting
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma (
INCB-99280-212
)
PD-L1 inhibitor,oral
Cutaneous squamous cell carcinoma
NSW
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NZ
NZ.3210 - Hamilton - Waikato Hospital
NCT05878288
Advanced
Phase 2
Active not recruiting
Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients (
DISCERN
)
Cemiplimab
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Cancer
Cutaneous squamous cell carcinoma
Non-melanoma skin cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05572463
Advanced
Phase 1 / Phase 2
Withdrawn
A Randomized, Open-label, Multicenter, Multi-arm, Phase 1b/2 Platform Study to Evaluate Safety and Efficacy of Investigational Immunotherapies in Participants With Previously Treated Unresectable or Metastatic Melanoma (
PLATFORM201
)
IBI110
Sintilimab
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
Cutaneous melanoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Active not recruiting (4)
Not yet recruiting (3)
Not yet recruiting (2)
Withdrawn (1)
Recruitment Country and State
QLD (14)
NSW (13)
VIC (5)
SA (4)
WA (4)
NZ (2)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (4)
Phase 2 (12)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (15)
Curative (6)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
68%
PD-1
55%
LAG3
18%
PD-L1
14%
IL-2
9%
SMO
9%
ALK
5%
MEK
5%
MET
5%
PKC
5%
ROS1
5%
MDM2
5%
JAK
5%
SYK
5%
VEGF
5%
Facility
4102 - Woolloongabba - Princess Alexandra Hospital (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (4)
2500 - Wollongong - Wollongong Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
6150 - Murdoch - GenesisCare Murdoch (1)
4215 - Southport - Tasman Oncology (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
6009 - Nedlands - One Clinical Research (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3168 - Clayton - Monash Medical Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
Cancer Type
Cancer
Skin cancer
Solid tumour
Non-melanoma skin cancer
Cutaneous squamous cell carcinoma
Melanoma
Gynaecological cancer
Carcinoma
Cutaneous melanoma
Head and neck cancer
Breast cancer
Gastrointestinal cancer
Head and neck squamous cell carcinoma
Cutaneous basal cell carcinoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Thoracic cancer
Upper gastrointestinal cancer
Urogenital cancer
Breast adenocarcinoma
Endometrial cancer
Triple-negative breast cancer
Merkel cell carcinoma
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Colorectal cancer
Lower gastrointestinal cancer
Non-small cell lung cancer
Bladder cancer
Cervical cancer
Uveal melanoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Mucosal melanoma
Squamous cell carcinoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Male genital cancers
Malignant glioma
Neurological cancer
Prostate cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
Follicular lymphoma
Haematological malignancy
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Clear cell renal cell carcinoma
Exocrine pancreatic cancer
Fallopian tube cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Kidney cancer
MSI-H/dMMR solid tumour
Mesothelioma
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Pancreatic adenocarcinoma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Squamous non-small-cell lung cancer
dMMR solid cancer
Anal cancer
Anal squamous cell carcinoma
Cutaneous in-transit melanoma metastasis
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy